Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“KRAS is no longer ‘undruggable.’
But that’s not the real question.
Why does targeting KRAS not lead to the same outcome across cancers?
Maybe KRAS is trying to teach us something.
Cancer is not just a mutation.
It’s a system. How that mutation develops, the microenvironment it lives in, the pathways it interacts with, and how resistance emerges…
This is what we need to understand. Because we now know: Targeting a single mutation is not enough. We need to target the network.”
Title: Context defines precision: rethinking KRAS inhibition in oncology
Author: Serena Marchiò
Read the full article on Precision Oncology.
Other articles featuring Ahmet Dirican on OncoDaily.